Episode 4: Virus-like Particles Based Vaccine Development Services for SARS-CoV-2 cover art

Episode 4: Virus-like Particles Based Vaccine Development Services for SARS-CoV-2

Episode 4: Virus-like Particles Based Vaccine Development Services for SARS-CoV-2

Listen for free

View show details

About this listen

 VLPs are multi-protein structures, which mimic the organization and conformation of authentic native viruses, but lack the viral genome, and may produce safer and cheaper vaccine candidates. If the specific native viral proteins with immunosuppressive function are excluded from VLPs, the efficacy of these particles can be significantly enhanced. Compared with single protein or peptide, VLPs present more similar conformational epitopes to the original virus. Therefore, antibody reactivity or immune system response is expected to be significantly improved. Due to their highly repetitive surfaces, VLPs are able to induce strong B cell responses without adjuvants by effectively crosslinking specific receptors on B cells. Studies have shown that VLP vaccines can stimulate humoral and cellular immune responses, thus providing effective antiviral protection.

What listeners say about Episode 4: Virus-like Particles Based Vaccine Development Services for SARS-CoV-2

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.